SGLT2 Inhibitors Ameliorate Adiposopathy and Inflammation in Diabetic and Non-Diabetic CKD

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

https://storage.unitedwebnetwork.com/files/1099/37a2007f6613ed012fcf6333aa3eb14b.pdf

Abstract Title *

SGLT2 Inhibitors Ameliorate Adiposopathy and Inflammation in Diabetic and Non-Diabetic CKD

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Luis D'Marco luis.dmarcogascon@uchceu.es CEU Cardenal Herrara University Medicine Valencia Spain *

Co-author 2

Owahabanun Joshua Okojie JOSHUA.OKOJIE1@alumnos.uchceu.es CEU Cardenal Herrara University Medicine Valencia Spain -

Co-author 3

Nelia Steib NELIA.STEIB@alumnos.uchceu.es CEU Cardenal Herrara University Medicine Valencia Spain -

Co-author 4

Oscar Arias oscar.ariasmutis@uchceu.es CEU Cardenal Herrara University Medicine Valencia Spain -

Co-author 5

Pilar Salvador salvadorMP@vithas.es Hospital Vithas Consuelo Medicine Valencia Spain -

Co-author 6

Isabel Fortea misabel.forteagorbe@uchceu.es CEU Cardenal Herrara University Medicine Valencia Spain -

Co-author 7

Ana Checa-Ros ana.checaros@uchceu.es CEU Cardenal Herrara University Medicine Valencia Spain -

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

This study assessed differences in adiposopathy and inflammatory biomarkers between type 2 diabetes (T2DM) and non-diabetic patients across chronic kidney disease (CKD) stages and investigated adipose tissue pathways for SGLT2 inhibitor (SGLT2i) renoprotection.

Methods

In an observational cohort study, 143 CKD patients were grouped into SGLT2i or Standard of Care (SoC) cohorts. Clinical and laboratory data were collected at baseline (T0) and after 8 months (T8).

Results

At T0, the SGLT2i group had higher cardiovascular risk and inflammatory markers (IL-6, TNF-α, ferritin), but lower leptin. After T8, renal function improved in the SGLT2i group but worsened in the SoC group. Most inflammatory markers decreased with SGLT2i, and leptin became significantly lower than in SoC. Specifically, dapagliflozin significantly reduced leptin and normalized elevated baseline TNF-α (Figure 1, 2 and 3).

Conclusion

SGLT2i confers renoprotective benefits by ameliorating adiposopathy and systemic inflammation, effects also confirmed in non-diabetic CKD patients

Kewords